[Gene therapy and cell therapy for idiopathic pulmonary arterial hypertension].
Idiopathic pulmonary arterial hypertension is a rare, but severe disease with high mortality. The endothelial dysfunction is a major pathogenesis of pulmonary arterial hypertension. Gene therapy, cell therapy and their combination therapy are developed to improve pulmonary hypertension by restoring the impaired endothelial function or regenerating endothelial cells. Although these therapies are still in experimental stage, they might be promising for pulmonary arterial hypertension. Here, we review the characteristics of the gene therapy, the cell therapy and the combination of them.
Takemiya
Kiyoko
K
Department of Internal Medicine, Division of Cardio-Vascular Medicine, Kurume University School of Medicine.
Kai
Hisashi
H
Imaizumi
Tsutomu
T
D000818:Animals; D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D015316:Genetic Therapy / Q000379:methods*; D006976:Hypertension, Pulmonary / Q000628:therapy*